Company Interview / Keep one eye on this small cap

Key points:

Contract with Hospital Corporation of America expands Technegas in the US.Technegas aids diverse medical conditions, from pulmonary embolism to asthma.Future focuses on execution, leveraging AI for improved patient care.

James McBrayer of Cyclopharm shares exciting news on Technegas, a leading nuclear medicine ventilation imaging agent. Cyclopharm signs a contract with the Hospital Corporation of America, allowing Technegas to be deployed across 169 nuclear medicine departments, expanding its footprint in the world's largest healthcare market, the USA.

Technegas, a unique combination of drug and device, faces regulatory challenges but is now gaining ground in the US. Initially developed in Australia, it aids in diagnosing pulmonary embolism and is now being explored for applications in asthma, COPD, and lung transplant evaluations. James notes increasing opportunities in both defence veterans' hospitals and commercial sectors in the US.

Looking forward, James emphasises execution and education in the US market, planning further expansion. Cyclopharm aims to leverage newer technologies, including AI, to enhance Technegas' efficacy as a prognostic tool, offering unprecedented lung condition details for improved patient care.